MX2023005529A - Metodos y composiciones que comprenden un inhibidor de krasg12c y un inhibidor de vegf para tratar tumores solidos. - Google Patents

Metodos y composiciones que comprenden un inhibidor de krasg12c y un inhibidor de vegf para tratar tumores solidos.

Info

Publication number
MX2023005529A
MX2023005529A MX2023005529A MX2023005529A MX2023005529A MX 2023005529 A MX2023005529 A MX 2023005529A MX 2023005529 A MX2023005529 A MX 2023005529A MX 2023005529 A MX2023005529 A MX 2023005529A MX 2023005529 A MX2023005529 A MX 2023005529A
Authority
MX
Mexico
Prior art keywords
inhibitor
methods
compositions
solid tumors
krasg12c
Prior art date
Application number
MX2023005529A
Other languages
English (en)
Inventor
Jennifer Lee Schutzman
Marie Evangelista
Mark Andrew Merchant
Ting- Kun Mark Lin
Stephanie Royer Joo
Sandhya Vinayak Mandlekar
Stuart G Lutzker
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2023005529A publication Critical patent/MX2023005529A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se proporcionan tratamientos conjuntos que comprenden un inhibidor de KRasG12C (por ejemplo, compuesto 1 o una sal farmacéuticamente aceptable de este) y un antagonista de VEGF (por ejemplo, bevacizumab) y métodos para usar tales tratamientos conjuntos.
MX2023005529A 2020-11-13 2021-11-11 Metodos y composiciones que comprenden un inhibidor de krasg12c y un inhibidor de vegf para tratar tumores solidos. MX2023005529A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063113609P 2020-11-13 2020-11-13
PCT/US2021/058877 WO2022103905A1 (en) 2020-11-13 2021-11-11 Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors

Publications (1)

Publication Number Publication Date
MX2023005529A true MX2023005529A (es) 2023-05-25

Family

ID=79185775

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005529A MX2023005529A (es) 2020-11-13 2021-11-11 Metodos y composiciones que comprenden un inhibidor de krasg12c y un inhibidor de vegf para tratar tumores solidos.

Country Status (11)

Country Link
US (1) US20220152030A1 (es)
EP (1) EP4243828A1 (es)
JP (1) JP2023550028A (es)
KR (1) KR20230088781A (es)
CN (1) CN116568326A (es)
AU (1) AU2021377810A1 (es)
CA (1) CA3201521A1 (es)
IL (1) IL301293A (es)
MX (1) MX2023005529A (es)
TW (1) TW202224682A (es)
WO (1) WO2022103905A1 (es)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
PT1787999E (pt) 1997-04-07 2010-11-11 Genentech Inc Anticorpos anti-vegf
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
ME00425B (me) 2003-05-30 2011-10-10 Genentech Inc Liječenje sa anti-vegf antitijelima
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
JOP20190272A1 (ar) * 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
AU2019377130B2 (en) * 2018-11-09 2022-03-17 F. Hoffmann-La Roche Ag Fused ring compounds

Also Published As

Publication number Publication date
WO2022103905A1 (en) 2022-05-19
TW202224682A (zh) 2022-07-01
US20220152030A1 (en) 2022-05-19
KR20230088781A (ko) 2023-06-20
CA3201521A1 (en) 2022-05-19
IL301293A (en) 2023-05-01
CN116568326A (zh) 2023-08-08
EP4243828A1 (en) 2023-09-20
JP2023550028A (ja) 2023-11-30
AU2021377810A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
CR20220258A (es) Inhibidores de kras g12c
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2021005924A (es) Compuestos y metodos de uso de los mismos para el tratamiento del cancer.
MX2021014177A (es) Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos.
MX2020007947A (es) Inhibidores de erbb/btk.
MX2020011907A (es) Inhibidores de kras g12c para el tratamiento de cancer.
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
MX2023008954A (es) Inhibidores de los receptores erbb.
AR111882A1 (es) Inhibidores de kras g12c y métodos para su uso
MX2022005053A (es) Inhibidores de peque?as moleculas de mutante g12c de kras.
HUS1600021I1 (hu) MEK inhibitorok és módszerek azok felhasználására
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
MX2021011606A (es) Compuestos dirigidos a prmt5.
WO2018183089A8 (en) Compositions for treating and/or preventing cancer
MX2022003537A (es) Terapias de combinacion.
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
MX2023006145A (es) Inhibidores de prmt5 novedosos.
MX2021002805A (es) Terapias de combinacion.
MX2022000933A (es) Inhibición de ezh2 en tratamientos combinados para el tratamiento del cáncer.
MX2021000051A (es) Inhibidores de triazol glicolato oxidasa.
MX2023004373A (es) Metodos y composiciones para la degradacion dirigida de proteinas.
MX2023005529A (es) Metodos y composiciones que comprenden un inhibidor de krasg12c y un inhibidor de vegf para tratar tumores solidos.
MX2023006690A (es) Procedimientos y composiciones que comprenden un inhibidor de krasg12c y un inhibidor de egfr para el tratamiento de tumores solidos.
MX2021009206A (es) Terapias contra el cancer.
MX2023005530A (es) Metodos y composiciones que comprenden un inhibidor de krasg12c y un antagonista de union a pd-l1 para tratar cancer de pulmon.